Neurology
- Active ingredient (INN)
- ethylmethylhydroxypyrine succinate
- Composition (active ingredients)
- ethylmethylhydroxypyridine succinate - 50,0 mg
- Фармакотерапевтическая группа
- antioxidant
- Pharmacotherapeutic group
- a solution for intravenous and intramuscular administration of 50 mg / ml 2 ml №10; 50 mg / ml 5 ml №5, 10
- Сonditions of supply
- on prescription
Indications
- acute cerebrovascular accident (as part of complex therapy);
- traumatic brain injury, consequences of traumatic brain injury;
- encephalopathy;
- syndrome of autonomic (neurocirculatory) dystonia;
- mild cognitive impairment of atherosclerotic origin;
- anxiety disorders in neurotic and neurosis-like conditions;
- acute myocardial infarction (from the first day) as part of complex therapy;
- primary open-angle glaucoma of various stages, as part of complex therapy;
- relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and autonomic-vascular disorders;
- acute intoxication with antipsychotic drugs;
- acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis) as part of complex therapy.
Dosage regimen
Intramuscularly or intravenously (stream or drip).
With the infusion method of administration, the drug should be diluted in a 0.9% sodium chloride solution.
Doses are selected individually.
Slowly injected slowly for 5-7 minutes, drip at a speed of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.
- In acute cerebrovascular accidents
-
used in complex therapy in the first 10-14 days - intravenously drip 200-500 mg 2-4 times a day, then intramuscularly 200-250 mg 2-3 times a day for 2 weeks
- With traumatic brain injury and the consequences of traumatic brain injury, the drug
-
used for 10-15 days, drip 200-500 mg 2-4 times a day
- With discirculatory encephalopathy in the decompensation phase
-
the drug is administered intravenously in a stream or drop at a dose of 200-500 mg 1-2 times a day for 14 days, then intramuscularly at 100-250 mg per day for the next two weeks
- For the course prevention of discirculatory encephalopathy
-
administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days
- With neurocirculatory dystonia, neurotic and neurosis-like conditions
-
the drug is administered intramuscularly at 50-400 mg per day for 14 days
- For mild cognitive impairment in elderly patients and anxiety disorders
-
the drug is administered intramuscularly at a dose of 100-300 mg per day for 14-30 days
- In acute myocardial infarction as part of complex therapy
-
the drug is administered intravenously or intramuscularly for 14 days, against the background of standard therapy for myocardial infarction (including nitrates, beta-blockers, angiotensin-converting enzyme inhibitors (ACEs), thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic indications). In the first 5 days, to achieve maximum effect, the drug is administered intravenously, in the next 9 days, the drug can be administered intramuscularly. Intravenous administration of the drug is carried out by drip infusion, slowly (to avoid side effects) for 30-90 minutes (in 100-150 ml of 0.9% sodium chloride solution or 5% dextrose (glucose) solution, if necessary, slow crusty intravenous administration the drug, lasting at least 5 minutes.The drug is administered (intravenously or intramuscularly) 3 times a day every 8 hours.The daily dose is 6-9 mg / ct body weight, a single dose is 2-3 mg / ct body weight. daily dose should not exceed 8 00 mg, single - 250 mg.
- With open-angle glaucoma of various stages, as part of complex therapy
-
administered intramuscularly at 100-300 mg per day, 1-3 times a day for 14 days
- With withdrawal alcohol syndrome
-
the drug is administered intramuscularly or intravenously in a dose of 200-500 mg 2-3 times a day for 5-7 days
- In acute intoxication with antipsychotic drugs
-
the drug is administered intravenously at a dose of 200-500 mg per day for 7-14 days
- In acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis)
-
the drug is prescribed on the first day both in the preoperative and in the postoperative period. The doses administered depend on the form and severity of the disease, the prevalence of the process, and options for the clinical course. Drug withdrawal should be done gradually only after a sustained positive clinical and laboratory effect.
- In acute edematous (interstitial) pancreatitis
-
the drug is prescribed 200-500 mg 3 times a day, intravenously drip (in 0.9% sodium chloride solution) and intramuscularly
- Mild severity of necrotic pancreatitis
-
100-200 mg 3 times a day, drip intravenously (in 0.9% sodium chloride solution) and intramuscularly. The average severity is 200 mg 3 times a day, drip intravenously (in a 0.9% sodium chloride solution). Severe course - at a dosage of 800 mg on the first day, with a double regimen of administration; then 200-500 mg 2 times a day with a gradual decrease in the daily dose. Extremely severe course - at an initial dosage of 800 mg per day until persistent relief of manifestations of pancreatogenic shock, to stabilize the state of 300-500 mg 2 times a day, intravenous drip (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage
